New insider Cicic Dragan claimed ownership of 118,584 shares (SEC Form 3)
$SLS
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 06/20/2024 |
3. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 118,584(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (2) | 03/12/2030 | Common Stock | 35,000 | $1.89 | D | |
| Stock Option (Right to Buy) | (3) | 03/04/2031 | Common Stock | 47,250 | $8 | D | |
| Stock Option (Right to Buy) | (4) | 01/31/2032 | Common Stock | 48,750 | $5.34 | D | |
| Stock Option (Right to Buy) | (5) | 02/02/2033 | Common Stock | 55,000 | $3.34 | D | |
| Stock Option (Right to Buy) | (6) | 01/22/2034 | Common Stock | 65,000 | $0.5195 | D | |
| Explanation of Responses: |
| 1. Consists of (i) 28,116 shares of Common Stock and (ii) 90,468 restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25,000 RSUs shall vest upon the satisfaction of performance-based vesting requirements, and 65,468 RSUs shall vest in one-quarter (1/4) increments annually on December 1 of each year provided that the Reporting Person remains in service with the Issuer through each such annual vesting date. |
| 2. One-quarter (1/4) of the option shares vested and became exercisable one year from the March 12, 2020 grant date, and the remainder vested and became exercisable in equal monthly installments for thirty-six (36) months thereafter. |
| 3. One-quarter (1/4) of the option shares vested and became exercisable one year from the March 4, 2021 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
| 4. One-quarter (1/4) of the option shares vested and became exercisable one year from the January 31, 2022 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
| 5. One-quarter (1/4) of the option shares vested and became exercisable one year from the February 2, 2023 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
| 6. One-quarter (1/4) of the option shares will vest and become exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
| Remarks: |
| Exhibit List - Exhibit 24 - Power of Attorney |
| /s/ Dragan Cicic | 06/27/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||